IO Biotech, a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win® technology platform, announced that it has dosed the first patient, in metastatic non-small cell lung cancer, in its Phase II IOB-022 / KN-D38 trial.
[IO Biotech]
6445212
BBBBBBBB
items
1
apa
0
default
asc
1
173959
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/